2001 - Sonnenwirth Award for Leadership in Clinical Microbiology, American Society for Microbiology
Peter H. Gilligan focuses on Microbiology, Cystic fibrosis, Internal medicine, Immunology and Lung. His Microbiology study frequently draws connections to adjacent fields such as Head and neck. His Cystic fibrosis research is multidisciplinary, relying on both Respiratory tract, Pseudomonas aeruginosa, Transmission, Sputum and Severe disease.
His Significant risk study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines. His Immunology course of study focuses on Nontuberculous mycobacteria and Mycobacterium abscessus. His work in Gastroenterology covers topics such as Surgery which are related to areas like Burkholderia cepacia complex.
Microbiology, Cystic fibrosis, Internal medicine, Immunology and Clostridium difficile are his primary areas of study. As a member of one scientific family, Peter H. Gilligan mostly works in the field of Microbiology, focusing on Burkholderia and, on occasion, Bacilli. His Cystic fibrosis research includes themes of Lung transplantation, Lung, Sputum and Mycobacterium abscessus.
His Internal medicine study incorporates themes from Gastroenterology, Antibiotics and Surgery. His studies deal with areas such as Respiratory system and Staphylococcus aureus as well as Immunology. Virology is closely connected to Immunoassay in his research, which is encompassed under the umbrella topic of Clostridium difficile.
His scientific interests lie mostly in Cystic fibrosis, Microbiology, Internal medicine, Mycobacterium abscessus and Immunology. The concepts of his Cystic fibrosis study are interwoven with issues in Antibiotics, Lung, Bronchiectasis, Intensive care medicine and Sputum. His work in the fields of Ocular Infections overlaps with other areas such as Infectious disease diagnosis.
The Internal medicine study combines topics in areas such as Gastroenterology, Clostridium difficile and Daptomycin. His Mycobacterium abscessus study integrates concerns from other disciplines, such as Clarithromycin, Clinical efficacy, Pseudomonas aeruginosa and Single Center. His work on Atopic dermatitis, Immune system and Pathogenesis as part of general Immunology study is frequently linked to Pediatric health, therefore connecting diverse disciplines of science.
Peter H. Gilligan spends much of his time researching Cystic fibrosis, Microbiology, Immunology, Lung and Mycobacterium abscessus. His work deals with themes such as Anaerobic bacteria, Colony-forming unit, Sputum, Anaerobic exercise and Bronchoalveolar lavage, which intersect with Cystic fibrosis. His study in Microbiology is interdisciplinary in nature, drawing from both Aerobic bacteria and Head and neck.
His Immunology study which covers Antibiotics that intersects with Pathogen, Pseudomonas aeruginosa, Pulmonary inflammation and Chronic infection. His Lung research integrates issues from Antibiotic resistance and Drug resistance. As a part of the same scientific family, Peter H. Gilligan mostly works in the field of Mycobacterium abscessus, focusing on Nontuberculous mycobacteria and, on occasion, Burkholderia, Multiple drug resistance and Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
Christina M Surawicz;Lawrence J Brandt;David G Binion;Ashwin N Ananthakrishnan.
The American Journal of Gastroenterology (2013)
Emergence of Vancomycin Resistance in Coagulase-Negative Staphylococci
Richard S. Schwalbe;Jack T. Stapleton;Peter H. Gilligan.
The New England Journal of Medicine (1987)
Microbiology of airway disease in patients with cystic fibrosis
Peter H. Gilligan.
Clinical Microbiology Reviews (1991)
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a
Ellen Jo Baron;J. Michael Miller;Melvin P. Weinstein;Sandra S. Richter.
Clinical Infectious Diseases (2013)
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
Josephine M Bryant;Josephine M Bryant;Dorothy M Grogono;Dorothy M Grogono;Daniela Rodriguez-Rincon;Isobel Everall.
A Pilot Study of Aerosolized Amiloride for the Treatment of Lung Disease in Cystic Fibrosis
Michael R Knowles;Nina L. Church;William E. Waltner;James R Yankaskas.
The New England Journal of Medicine (1990)
Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis.
Charles R. Esther;Denise A. Esserman;Peter Gilligan;Alan Kerr.
Journal of Cystic Fibrosis (2010)
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology
J. Michael Miller;Matthew J. Binnicker;Sheldon Campbell;Karen C. Carroll.
Clinical Infectious Diseases (2018)
Breakthrough Pneumococcal Bacteremia in Patients Being Treated with Azithromycin and Clarithromycin
Meera A. Kelley;David J. Weber;Peter Gilligan;Myron S. Cohen.
Clinical Infectious Diseases (2000)
Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type.
Robert M. Aris;Jonathan C. Routh;Jonathan C. Routh;John J. LiPUMA;John J. LiPUMA;David G. Heath;David G. Heath.
American Journal of Respiratory and Critical Care Medicine (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: